Top editors picks!

Pfizer Wants To Throw Its Hat Into The Ring With Up To $6 Billion 3SBio Deal

Bristol-Myers Squibb Fails Phase 3 Study With Cobenfy

In Flight To Enact Strategic Alternatives, Tempest Cuts 80% of its Workforce

Rallybio Scraps Maternal Disorder Candidate RLYB212 Shifting Focus To C5 Inhibitor

Rhythm Pharmaceuticals Scores A Win For Obesity Disorder Caused By Impairment Of The Brain

Beigene’s Anti-TIGIT Trial Closure Doesn’t Bode Well For This Drug Class Going Forward

Sangamo Gets Lifeline From Eli Lilly In $1.4 Billion Dollar Deal For Proprietary AAV Capsid

Second FDA Rejection Of Aldeyra Therapeutics But Hope Remains With Two Upcoming Events

Latest Corcept Data Could Lead To New Standard Of Care Option for Platinum-Resistant Ovarian Cancer Patients

Cassava Sciences Scraps Alzheimer’s Drug Development Of Simufilam After Latest Trial Failure

Lexicon Establishes $1 Billion Milestone Deal With Novo Nordisk To Advance Weight Loss Drug LX9851

Scroll to Top